129 related articles for article (PubMed ID: 37105784)
41. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database.
Hamad A; Underhill J; Ansari A; Thayaparan V; Cloyd JM; Li Y; Pawlik TM; Tsung A; Abushahin L; Ejaz A
Surgery; 2022 Jun; 171(6):1464-1470. PubMed ID: 35115154
[TBL] [Abstract][Full Text] [Related]
42. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial.
Snady H; Bruckner H; Cooperman A; Paradiso J; Kiefer L
Cancer; 2000 Jul; 89(2):314-27. PubMed ID: 10918161
[TBL] [Abstract][Full Text] [Related]
43. Prognostic analysis of patients with pancreatic head adenocarcinoma less than 2 cm undergoing resection.
Chiang KC; Yeh CN; Lee WC; Jan YY; Hwang TL
World J Gastroenterol; 2009 Sep; 15(34):4305-10. PubMed ID: 19750574
[TBL] [Abstract][Full Text] [Related]
44. Clinical predictors of resectability of pancreatic adenocarcinoma.
Almadi MA; Alharbi O; Azzam N; Altayeb M; Javed M; Alsaif F; Hassanain M; Alsharabi A; Al-Saleh K; Aljebreen AM
Saudi J Gastroenterol; 2013; 19(6):278-85. PubMed ID: 24195982
[TBL] [Abstract][Full Text] [Related]
45. A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma.
Reni M; Berardi R; Mambrini A; Pasetto L; Cereda S; Ferrari VD; Cascinu S; Cantore M; Mazza E; Grisanti S
Cancer Chemother Pharmacol; 2008 Sep; 62(4):673-8. PubMed ID: 18172650
[TBL] [Abstract][Full Text] [Related]
46. Pancreatic adenocarcinoma: a review for primary care physicians.
Postier RG; Williams GR
J Okla State Med Assoc; 1993 Oct; 86(10):492-5. PubMed ID: 7504097
[TBL] [Abstract][Full Text] [Related]
47. Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma.
Moghanaki D; Mick R; Furth EE; Sohal D; Salmon PM; Behbahani A; Morgans AK; Miller SM; Giantonio BJ; Whittington RW; Haller DG; Rosato EF; Plastaras JP
JOP; 2011 Sep; 12(5):438-44. PubMed ID: 21904068
[TBL] [Abstract][Full Text] [Related]
48. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Tempero MA; Malafa MP; Al-Hawary M; Asbun H; Bain A; Behrman SW; Benson AB; Binder E; Cardin DB; Cha C; Chiorean EG; Chung V; Czito B; Dillhoff M; Dotan E; Ferrone CR; Hardacre J; Hawkins WG; Herman J; Ko AH; Komanduri S; Koong A; LoConte N; Lowy AM; Moravek C; Nakakura EK; O'Reilly EM; Obando J; Reddy S; Scaife C; Thayer S; Weekes CD; Wolff RA; Wolpin BM; Burns J; Darlow S
J Natl Compr Canc Netw; 2017 Aug; 15(8):1028-1061. PubMed ID: 28784865
[TBL] [Abstract][Full Text] [Related]
49. The clinical utility of biomarkers in the management of pancreatic adenocarcinoma.
Jazieh KA; Foote MB; Diaz LA
Semin Radiat Oncol; 2014 Apr; 24(2):67-76. PubMed ID: 24635863
[TBL] [Abstract][Full Text] [Related]
50. 18F-FDG-PET/CT therapy assessment of locally advanced pancreatic adenocarcinoma: impact on management and utilization of quantitative parameters for patient survival prediction.
Sheikhbahaei S; Wray R; Young B; Mena E; Taghipour M; Rahmim A; Subramaniam RM
Nucl Med Commun; 2016 Mar; 37(3):231-8. PubMed ID: 26575392
[TBL] [Abstract][Full Text] [Related]
51. Pancreatic neoplasm in 2011: an update.
Saif MW
JOP; 2011 Jul; 12(4):316-21. PubMed ID: 21737886
[TBL] [Abstract][Full Text] [Related]
52. Trends in and Prognostic Significance of Time to Treatment in Pancreatic Cancer: A Population-Based Study.
Sugumar K; Hue JJ; Gupta S; Elshami M; Rothermel LD; Ocuin LM; Ammori JB; Hardacre JM; Winter JM
Ann Surg Oncol; 2023 Dec; 30(13):8610-8620. PubMed ID: 37624518
[TBL] [Abstract][Full Text] [Related]
53. Determinants of patient's and doctor's delay in diagnosis and treatment of colorectal cancer.
Van Hout AM; de Wit NJ; Rutten FH; Peeters PH
Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):1056-63. PubMed ID: 21941190
[TBL] [Abstract][Full Text] [Related]
54. Translational research. New findings and potential future applications in pancreatic adenocarcinoma.
Strimpakos AS; Syrigos KN; Saif MW
JOP; 2012 Mar; 13(2):177-9. PubMed ID: 22406595
[TBL] [Abstract][Full Text] [Related]
55. Metastases of pancreatic adenocarcinoma: A systematic review of literature and a new functional concept.
Cannistrà M; Ruggiero M; Zullo A; Serafini S; Grande R; Nardo B
Int J Surg; 2015 Sep; 21 Suppl 1():S15-21. PubMed ID: 26123383
[TBL] [Abstract][Full Text] [Related]
56. External radiation is associated with limited improvement in overall survival in resected margin-negative stage IIB pancreatic adenocarcinoma.
Kantor O; Talamonti MS; Lutfi W; Wang CH; Winchester DJ; Marsh R; Prinz RA; Baker MS
Surgery; 2016 Dec; 160(6):1466-1476. PubMed ID: 27614417
[TBL] [Abstract][Full Text] [Related]
57. [Value of combined therapy in pancreatic cancer with a poor prognosis: analysis of 233 clinical cases].
Wang Y; Zhao P; Wang CF; Shan Y; Zhao DB; Tian YT; Sun YM; Che X; Zhang JW
Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(34):2381-5. PubMed ID: 20137689
[TBL] [Abstract][Full Text] [Related]
58. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?
Schnelldorfer T; Ware AL; Sarr MG; Smyrk TC; Zhang L; Qin R; Gullerud RE; Donohue JH; Nagorney DM; Farnell MB
Ann Surg; 2008 Mar; 247(3):456-62. PubMed ID: 18376190
[TBL] [Abstract][Full Text] [Related]
59. Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort.
Al-Husseini MJ; Saad AM; Turk T; Tabash MA; Abdel-Rahman O
J Gastrointest Cancer; 2019 Dec; 50(4):794-800. PubMed ID: 30105523
[TBL] [Abstract][Full Text] [Related]
60. [Trends for the management of pancreatic adenocarcinoma in a hospitalized-based population (1980-1994)].
Queneau PE; Pitard A; Labourey JM; Koch S; Sauve G; Carayon P
Gastroenterol Clin Biol; 2000 May; 24(5):501-5. PubMed ID: 10891737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
